1. Home
  2. BAFN vs NYXH Comparison

BAFN vs NYXH Comparison

Compare BAFN & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

HOLD

Current Price

$6.82

Market Cap

175.3M

Sector

Finance

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

BUY

Current Price

$0.81

Market Cap

137.5M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
BAFN
NYXH
Founded
1999
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Savings Institutions
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
175.3M
137.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
BAFN
NYXH
Price
$6.82
$0.81
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $4.20
AVG Volume (30 Days)
103.5K
★ 202.7K
Earning Date
10-29-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$275.91
Revenue Next Year
N/A
$93.27
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.26
$0.88
52 Week High
$9.80
$5.92

Technical Indicators

Market Signals
Indicator
BAFN
NYXH
Relative Strength Index (RSI) 50.60 21.64
Support Level $5.98 N/A
Resistance Level $6.96 $1.69
Average True Range (ATR) 0.62 0.06
MACD 0.07 -0.05
Stochastic Oscillator 58.04 3.07

Price Performance

Historical Comparison
BAFN
NYXH

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: